Physician profile
William Calley
NPI 1467763961
$7,055.91
in general payments reported to CMS, 2019-2025
48 companies · $962 in 2025
The $962 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $906 · 2021: $1,420 · 2022: $871 · 2023: $1,141 · 2024: $892 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,994.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,234.41 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $827.39 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $595.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $541.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $465.64 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $433.37 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $345.43 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Lilly USA, LLC | $274.21 | 2019-2025 | Jardiance, Emgality, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $248.60 | 2019-2023 | Trintellix |
| Esperion Therapeutics, INC. | $206.17 | 2020-2025 | Nexletol |
| Eisai INC. | $175.62 | 2020-2022 | |
| Exact Sciences Corporation | $150.87 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $138.57 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.89 | 2021-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $117.57 | 2022-2025 | Rexulti |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Calley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.